Gilead Sciences Sees Strong Revenue Growth in Q2 2026
Source: yahoo ·
Gilead Sciences posted a 10% revenue increase to $7.8 billion in Q2 2026, driven by growth across HIV, oncology, and liver disease.
Key takeaways
- Gilead Sciences reported a 10% year-over-year increase in total revenue to $7.8 billion in fiscal Q2 2026.
- The company's product sales rose 8% to $7.6 billion, driven by growth in HIV, oncology, and liver disease.
- Gilead reported a substantial quarterly loss after recording $11 billion in acquired research and development expenses.
- The company raised the lower end of its 2026 product-sales guidance to $30.1-30.4 billion.
- Gilead's underlying business performed strongly, with product sales excluding Veklury increasing 10% to $7.6 billion.
Why it matters
Gilead's commercial business is performing well, driven by growth in HIV, oncology, and liver disease. However, investors must weigh the company's operational momentum against its reported profitability, which was impacted by substantial acquired research and development expenses. The company's acquisitions and pipeline programs will be key drivers of its future growth, and investors should monitor regulatory approvals and product launches for these programs to understand their potential impact on the company's stock price.
What to watch
- Gilead's upcoming earnings date for fiscal Q3 2026, which will provide further insight into the company's commercial momentum.
- The company's plans for its acquired pipeline programs, including Arcellx, Tubulis, and Ouro Medicines.
- Regulatory approvals and product launches for Gilead's pipeline programs, which will impact the company's future growth.